.
MergerLinks Header Logo

Announced

Completed

Sequoia Capital led a $200m Series E round in Benchling.

Financials

Edit Data
Transaction Value£145m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Completed

Venture Capital

Private Equity

Single Bidder

life sciences

Private

Acquisition

Biotechnology

Minority

United States

Friendly

Cross Border

biotechnology

Synopsis

Edit

Investment firm Sequoia Capital led a $200m Series E round in Benchling, a life sciences R&D cloud, with participation from Altimeter Capital, Byers Capital, Elad Gil, Thrive Capital, Benchmark, Menlo Ventures, Alkeon Capital, ICONIQ, Lux Capital, Spark Capital and Lead Edge Capital. "Recent breakthroughs in biology have the potential to transform the world in the same way that computing and the internet did. We are relying on scientists to rewrite the medicines we take, the food we eat, and the fuels that power our lives. We are excited to partner with Benchling as they build the foundational software infrastructure for the scientists redefining the world," Patrick Fu, Sequoia Capital Managing Partner.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US